Phase I/II Study of SCTB39G in Advanced Solid Tumours

Inclusion Criteria: * 1.Voluntarily sign the informed consent form (ICF); * 2.Male or female, ≥ 18 years and ≤ 70 years old; * 3.Survival duration more than 3 months; * 4.ECOG score ≤ 1 point; * 5.histologically or cytologically confirmed diagnosis of advanced malignant solid tumour； * 6.At least one measurable tumor lession according to RECIST v1.1; * 7.Adequate organ and bone marrow function. Exclusion Criteria: * 1.Has participated in another clinical study within 4 weeks prior to the first dose; * 2.Other malignancies diagnosed within 1 years prior to the enrollment; * 3\. Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases; * 4.NSCLC at high risk of bleeding; Obvious invasion of tumor into adjacent organs of esophageal lesions leads to high risk of bleeding or fistula,or participants after endotracheal stent implantation; * 5.Participants with portal hypertension due to portal vein tumor thrombus at risk of bleeding; * 6.Presence of pleural effusion, peritoneal effusion, or ascites; * 7.Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment * 8.History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs; * 9.Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence; * 10.History of severe allergies, severe drug allergies (including unapproved investigational drugs); * 11.History of organ transplantation or stem cell transplantation; * 12.Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study; * 13.Pregnant or breastfeeding female.